Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT Launches Ground-Breaking 58-Gene Tumour Profiling Service

Published: Tuesday, May 28, 2013
Last Updated: Tuesday, May 28, 2013
Bookmark and Share
This Technology Strategy Board-funded, government-backed assay performs significantly better than standard tests.

Oxford Gene Technology (OGT) has furthered its commitment to fighting cancer with the launch of a new solid tumour profiling next-generation sequencing service to advance vital research into personalised cancer care. OGT is the first commercial facility in the UK to offer this service.

OGT’s SureSeq™ Solid Tumour Panel Sequencing Service profiles the mutations of patient tumours for 58 cancer-associated genes prioritised by Cancer Research UK and leading cancer researchers. The genes include those important in breast, prostate, ovarian, lung and colorectal cancers, many with currently actionable mutations.  OGT also offers researchers the flexibility to further customise the panel by adding additional genes of interest.

The panel of 58 genes was developed in collaboration with researchers at the Salisbury and Birmingham NHS Regional Genetics Laboratories as part of a £1.16 million funding award from the UK Government-backed Technology Strategy Board’s Stratified Medicines programme. The ultimate aim of the programme is to improve patient care and achieve significant cost savings over the single gene tests currently available. OGT has applied its extensive expertise in probe design to Agilent’s industry-leading SureSelect™ hybridisation methodology, to deliver an assay with unparalleled uniformity of targeted sequence enrichment, excellent accuracy and sensitivity of variant detection across full genes, and robust performance with FFPE samples. All results are delivered in a comprehensive interactive web-based report to enable informed interpretation of results.

Dr Mike Evans, CEO at OGT said: “We are committed to tackling cancer by developing tools for cancer research, such as biomarkers for early detection and tumour profiling assays, such as SureSeq. This comprehensive, full-gene assay allows clinical researchers to accurately identify known and de novo mutations, enabling the development of informed, personalised cancer treatment strategies. We are proud to be working alongside the Technology Strategy Board and NHS in order to revolutionise cancer profiling and treatment.”

The project partners, including Salisbury and Birmingham NHS Regional Genetics Laboratories, validated the tumour profiling assay with fresh, frozen and formalin-fixed, paraffin-embedded (FFPE) samples. In a blind study of previously genotyped clinical samples, the assay accurately detected all variants present. Through expert probe design by OGT and improved uniformity of sequence enrichment, the assay also delivered an improved likelihood of variant discovery across all regions of the genes, enabling the detection of low-frequency somatic variants in heterogeneous cancer samples.

Dr Alasdair Gaw, Lead Technologist, Stratified Medicine at the UK’s innovation agency, the Technology Strategy Board said: “We are pleased with the progress made by OGT and its partners in the development of this new tumour profiling assay. We are confident that the implementation of such assays will significantly advance our understanding of cancer, enabling stratified medicine and the development of personalised cancer treatment regimes that will significantly improve patient care.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT’s Popular ESHG Workshop Free to View Online
Learn about the next generation of microarrays in one of the best attended workshops of the conference.
Friday, July 17, 2015
OGT Signs License with Wellcome Trust Sanger Institute
OGT will use novel data on developmental disorders to advance microarray and NGS products for accurate and cost effective identification of rare diseases.
Saturday, April 04, 2015
Oxford Gene Technology Awarded £1.2m Genomics England Contract
Next Generation Sequencing analysis software will support 100,000 Genomes Project by providing intuitive reports for clinical interpretation.
Monday, March 16, 2015
OGT Announces Operational and Financial Highlights for FY 2014
OGT’s molecular genetics business delivers 54% growth in commercial revenues to £11.9m.
Tuesday, December 09, 2014
Pieces of the Puzzle - A Multi-method Approach to Tumour Profiling
OGT workshop provides insight on using complementary genomic technologies.
Friday, November 07, 2014
An Integrated Approach to Clinical Genetics Research
OGT’s new whitepaper explores the next stage of molecular testing.
Wednesday, April 09, 2014
OGT Announces Acquisition of Cytocell Ltd
Company expands leadership in genomic medicine.
Thursday, March 06, 2014
Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
New Whitepaper Compares Targeted Resequencing Strategies
OGT provides insight into choice of NGS methods.
Wednesday, July 17, 2013
OGT Initiates Strategic Expansion Plans in North America
Opening of New York office and appointment of US sales team.
Tuesday, November 20, 2012
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!